Home » Newsletters » BioWorld Science

BioWorld Science

July 4, 2007

View Archived Issues

Novel antiinflammatory agents disclosed in recent patent literature

Studies reveal potential of CS-917 in type 2 diabetes

Studies advance immunomodulating agents for diabetes

Phase II findings warrant advancement of ispinesib for breast cancer

New data on treatments for diabetic complications: neuropathy, gastroparesis

Proof of concept obtained for HMPL-004 in ulcerative colitis

Recent patents impart new therapeutic agents for respiratory disorders

FemmePharma initiates clinical trial for pain associated with breast disease

Bayer introduces more convenient formulation of Kogenate FS

4SC completes enrollment for a phase IIa trial for rheumatoid arthritis

Cylene Pharmaceuticals initiates phase II trial of Quarfloxin for cancer

New data indicate activity of perifosine in multiple myeloma

FDA approves clinical trials of ralfinamide for neuropathic pain

Wilex to file SPA for CA9-SCAN

Karo Bio delays development of KB-5359 for dyslipidemia

New agents for renal and urological disorders reported by Toray

Novel long-acting GLP-1 analogues presented at the ADA meeting

Novel adenosine A2B receptor antagonist improves insulin sensitivity in vivo

Newly identified frog-derived ribonuclease could be a future cancer therapy

Wyeth and Karo Bio extend atherosclerosis collaboration

Positive phase I/II results for ALKS-29 in alcohol-dependent patients

Phase I data indicate activity of Quadramet in multiple myeloma

Positive results of subcutaneous methylnaltrexone extension study

Santhera inlicenses omigapil for congenital muscular dystrophy

New data support role of Velcade in front-line multiple myeloma treatment

SIRT2: a new target in Parkinson's disease

Tamiflu approved in 30 mg and 45 mg doses

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...